CytomX Therapeutics

CytomX Therapeutics Employees

9 people indexed:

Chris Ogden

SVP, Finance and Accounting

fiv22r@119vzh.85u Sign up to see email

a6jpbf@32r4r3.0iv Sign up to see email
Danielle Olander-Moghadassian

SVP, Chief Human Resources Officer

f51v5w1vww277jf89j195@1b45v8.bk6 Sign up to see email

2bp9juvf3quw470fp52j9@07vkk5.3fq Sign up to see email
Dawn Benson

SVP, Quality and Product Manufacturing

68055ia@wkv3g7.a69 Sign up to see email

ug4kg3r@7ir52g.g7u Sign up to see email
Jeff Landau

SVP, Head of Strategy and Chief Business Officer

4ez9shv@4iqvk7.spq Sign up to see email

0er7e54@5h825h.rv1 Sign up to see email
Leslie Robbins

SVP, Intellectual Property

gjju1j8d@ezzg9v.e64 Sign up to see email

hwhvewjf@7u93he.93u Sign up to see email
Lloyd A. Rowland, Jr.

SVP, General Counsel, Secretary and Chief Compliance Officer

85.4692ses.vp@5z1813.0g6 Sign up to see email

8f.u6i6ei5.pb@p5q04k.eef Sign up to see email
Marcia P. Belvin

SVP, Chief Scientific Officer

3r.hg2wk4@10krwh.jr5 Sign up to see email

j5.94rdg1@s41581.9g3 Sign up to see email
Sean A. McCarthy

Chief Executive Officer and Chairman

0i.2uu8739d@bwdw62.p0q Sign up to see email

0u.u2gwbulp@31u530.46i Sign up to see email
Wayne Chu

Chief Medical Officer

1bld@8pi26v.9bz Sign up to see email

nvk4@2qbk5e.qvj Sign up to see email

CytomX Therapeutics Company Information

CytomX Therapeutics, established in 2008, is headquartered in South San Francisco, California. The company focuses on the development of Probody therapeutics, which are engineered to improve cancer treatment efficacy by localizing therapeutic effects within the tumor microenvironment while reducing the impact on healthy tissues. This innovative approach leverages the unique conditions of tumor sites to optimize treatment outcomes. CytomX has developed a broad, clinical-stage pipeline that includes multiple Probody programs currently undergoing clinical trials. Furthermore, the company has formed strategic collaborations with several leading oncology entities, such as Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna, aiming to transform the landscape of cancer treatment through advanced therapeutic options.

Report inaccurate information